TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31109201

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (56 or 84 mg twice weekly) plus newly initiated antidepressant
Number of subjects: 227

Group type: COMPARATOR
Intervention: Antidepressant plus placebo nasal spray
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus antidepressant
Number of subjects: 227
Study: 28370745

Group type: EXPERIMENTAL
Intervention: Disposable diaper products
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adult incontinence products
Number of subjects: 0
Study: 26444879

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 374

Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 374
Study: 24103587

Group type: EXPERIMENTAL
Intervention: Citrate dialysis fluid (1 mM citrate, 1.5 mM calcium)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control fluid (3 mM acetate, 1.5 mM calcium)
Number of subjects: 20
Study: 21311345

Group type: EXPERIMENTAL
Intervention: Concurrent training (CG)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aerobic training (EG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Strength training (SG)
Number of subjects: 23
Study: 19685935

Group type: EXPERIMENTAL
Intervention: Hypotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Isotonic PEG (12 g once or twice daily or once every other day for 4 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Hypotonic PEG
Number of subjects: 62

Group type: COMPARATOR
Intervention: Isotonic PEG
Number of subjects: 62
Study: 17074112

Group type: EXPERIMENTAL
Intervention: Alendronate, 10 mg/d
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Tibolone, 1.25 mg/d
Number of subjects: 185

Group type: COMPARATOR
Intervention: Calcium preparation only
Number of subjects: 185
Study: 15330687

Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 419

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 419
Study: 11587703

Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 52
Study: 9024732

Group type: EXPERIMENTAL
Intervention: 15 g/day supplemental water‐soluble dietary fiber (WSDF; a mixture of psyllium, pectin, guar gum, and locust bean gum)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Inactive WSDF control (acacia gum)
Number of subjects: 51
Study: 8388352

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins administered subcutaneously
Number of subjects: 0
Study: 3326044

Group type: EXPERIMENTAL
Intervention: Piracetam 2 x 3g
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Piracetam 2 x 12g
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 29890086

Group type: EXPERIMENTAL
Intervention: Azithromycin (3× weekly) with standardized tobramycin inhalation solution (TIS)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo with standardized tobramycin inhalation solution (TIS)
Number of subjects: 221
Study: 27607859

Group type: EXPERIMENTAL
Intervention: Quickstart group (depot medroxyprogesterone acetate with mifepristone)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Afterstart group (depot medroxyprogesterone acetate after abortion)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Quickstart group
Number of subjects: 461

Group type: COMPARATOR
Intervention: Afterstart group
Number of subjects: 461
Study: 25333437

Group type: EXPERIMENTAL
Intervention: Antimicrobial coating on scrubs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antimicrobial coating)
Number of subjects: 0
Study: 23419913

Group type: EXPERIMENTAL
Intervention: Multimodal physical therapies
Number of subjects: 181
Study: 21170106

Group type: EXPERIMENTAL
Intervention: Alprostadil cream 500 μg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Alprostadil cream 700 μg
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Alprostadil cream 900 μg
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 400
Study: 18668406

Group type: EXPERIMENTAL
Intervention: 4 hr sampling duration
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 2 hr sampling duration
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 1 hr or less sampling duration
Number of subjects: 138

Group type: COMPARATOR
Intervention: Full-shift measurements
Number of subjects: 138
Study: 16167268

Group type: EXPERIMENTAL
Intervention: Boxers
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 11
Study: 12511361

Group type: EXPERIMENTAL
Intervention: Artisan toric phakic intraocular lenses (TPIOLs) implantation
Number of subjects: 53
Study: 11334057

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF at a dose of 5.0 microg/kg/day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 43
Study: 8803380

Group type: EXPERIMENTAL
Intervention: Fentanyl citrate, hydromorphone hydrochloride, methadone hydrochloride, and morphine sulfate solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin sodium
Number of subjects: 0
Study: 1536216

Group type: EXPERIMENTAL
Intervention: Self-nonstress test
Number of subjects: 60

Group type: COMPARATOR
Intervention: Assisted nonstress test
Number of subjects: 60
Study: 6402914

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 60 mg/day orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30275356

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PLCB)
Number of subjects: 20
Study: 25820921

Group type: EXPERIMENTAL
Intervention: Family-based exposure with response prevention
Number of subjects: 127
Study: 24898680

Group type: EXPERIMENTAL
Intervention: Preoperative and early postoperative rehabilitation (starting two weeks after surgery)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Preoperative and late postoperative rehabilitation (starting six weeks after surgery)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Early postoperative rehabilitation alone
Number of subjects: 380

Group type: COMPARATOR
Intervention: Today's standard care (postoperative rehabilitation initiated six weeks after surgery)
Number of subjects: 380
Study: 23116022

Group type: EXPERIMENTAL
Intervention: Immunomodulator Lavomax and basic treatment: azithromycin (1.0 g once a week for 3 weeks), Celebrex, physiotherapy (low‐intensity laser radiation), prostate massage
Number of subjects: 114

Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 114
Study: 19536571

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 25% protrusion position
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 50% protrusion position
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) at 75% protrusion position
Number of subjects: 17
Study: 18609142

Group type: EXPERIMENTAL
Intervention: telaprevir (VX-950)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Peg‐IFN plus telaprevir
Number of subjects: 54

Group type: COMPARATOR
Intervention: Peg‐IFN plus placebo
Number of subjects: 54
Study: 16022758

Group type: EXPERIMENTAL
Intervention: High glycaemic index (HGI) trial
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) trial
Number of subjects: 9
Study: 14619336

Group type: EXPERIMENTAL
Intervention: Steroid resistant (SR) patients
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Steroid sensitive (SS) patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Bronchial wall thickness
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Comparison between SR and SS patients
Number of subjects: 23
Study: 11094034

Group type: EXPERIMENTAL
Intervention: PTA plus BT (57 patients)
Number of subjects: 113

Group type: COMPARATOR
Intervention: PTA (56 patients)
Number of subjects: 113
Study: 8683967

Group type: EXPERIMENTAL
Intervention: 1.00 g/kg alcohol dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.25 g/kg alcohol dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.50 g/kg alcohol dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2003373

Group type: EXPERIMENTAL
Intervention: Acupuncture twice a week for two months
Number of subjects: 17
Study: 6342554

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 79

Group type: COMPARATOR
Intervention: 2.5% albumin‐lactated Ringer's solution
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 79

Group type: COMPARATOR
Intervention: Crystalloid group
Number of subjects: 79
Study: 31867833

Group type: EXPERIMENTAL
Intervention: One-to-one speech and language therapist (SLT) intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Classroom-based intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: One-to-one SLT intervention
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Idiom explanation skills
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Idiom use skills
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control items
Number of subjects: 49
Study: 30852854

Group type: EXPERIMENTAL
Intervention: Intimacy-enhancing therapy (IET)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: General health and wellness intervention (GHW)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 237
Study: 29600580

Group type: EXPERIMENTAL
Intervention: Acitretin (0.4 mg/kg per day) plus nanocurcumin (3 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acitretin
Number of subjects: 0
Study: 27864247

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-delivered structured intervention at discharge and tailored follow-up postdischarge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist delivered usual care at discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (patients discharged during weekends or after hours)
Number of subjects: 0
Study: 25143372

Group type: EXPERIMENTAL
Intervention: A&T social franchise model (A&T-I; mass media + social franchise)
Number of subjects: 2045

Group type: COMPARATOR
Intervention: A&T nonintensive areas (A&T-NI; mass media only)
Number of subjects: 2045
Study: 21913224

Group type: COMPARATOR
Intervention: Safinamide 200 mg
Number of subjects: 269

Group type: COMPARATOR
Intervention: Safinamide 100 mg
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 269
Study: 17559536

Group type: EXPERIMENTAL
Intervention: 10‐minute sodium hypochlorite (NaOCl)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 1‐hour sodium hypochlorite (NaOCl)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No disinfectant
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Disinfected PE impressions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Non-disinfected and disinfected VPS and PE impressions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All disinfectants (NaOCl and dual phenol)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increasing exposure to NaOCl
Number of subjects: 50
Study: 10861157

Group type: EXPERIMENTAL
Intervention: 5 mg intramuscular midazolam
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 55
Study: 9202789

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 1532321

Group type: EXPERIMENTAL
Intervention: Captopril (AA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Captopril (AP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PP)
Number of subjects: 20
Study: 3572102

Group type: EXPERIMENTAL
Intervention: Levamisole as an immuno-stimulator for 1 year along with chemotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 20
Study: 30502984

Group type: EXPERIMENTAL
Intervention: Subcutaneous tranexamic acid (TXA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 34
Study: 25539571

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EN)
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Early parenteral nutrition (PN)
Number of subjects: 2854
Study: 22520084

Group type: EXPERIMENTAL
Intervention: Vilanterol 6.25 mcg once-daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vilanterol 12.5 mcg once-daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vilanterol 25 mcg once-daily
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Vilanterol 6.25 mcg twice-daily
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 20500310

Group type: EXPERIMENTAL
Intervention: Self-care self-efficacy enhancement programme (SCSEEP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 101
Study: 18347203

Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Respiratory rehabilitation (RR)
Number of subjects: 64
Study: 16179089

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (n = 245)
Number of subjects: 490

Group type: COMPARATOR
Intervention: artesunate and mefloquine (n = 245)
Number of subjects: 490
Study: 12087881

Group type: EXPERIMENTAL
Intervention: Interrupted normobaric hypoxia (INH)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 10622344

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 9138981

Group type: EXPERIMENTAL
Intervention: Oxytocin induced labor (PI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Emergency cesarean section (CCC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Elective cesarean section (CCE)
Number of subjects: 82
Study: 1916007

Group type: EXPERIMENTAL
Intervention: 1 g/day alpha‐glycerylphosphorylcholine (alpha‐GPC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1 g/day cytosine diphosphocholine (CDP)
Number of subjects: 120
Study: 30291532

Group type: EXPERIMENTAL
Intervention: Religious intervention (12 sessions of 30-45 minutes each)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 30969960

Group type: EXPERIMENTAL
Intervention: Praziquantel from Nanjing Pharmaceutical Factory (NPF), China
Number of subjects: 152

Group type: COMPARATOR
Intervention: Praziquantel from Merck Limited Partnership (KgaA), Germany
Number of subjects: 152
Study: 27662605

Group type: EXPERIMENTAL
Intervention: Mtwo rotary NiTi files
Number of subjects: 130

Group type: COMPARATOR
Intervention: SAF (self-adjusting file) system
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: SAF group (teeth with vital pulps)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: SAF group (teeth with nonvital pulps)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Teeth with pulpal necrosis
Number of subjects: 130
Study: 26110636

Group type: EXPERIMENTAL
Intervention: Yohimbine (alpha2-adrenergic antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial stress protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study: 23831177

Group type: EXPERIMENTAL
Intervention: Treatment as usual combined with animal-assisted therapy (AAT) administered over 10 weekly sessions
Number of subjects: 65

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 65
Study: 21594587

Group type: EXPERIMENTAL
Intervention: Immediate intervention (12-week web-based support group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 27
Study: 20024643

Group type: EXPERIMENTAL
Intervention: BNP concentration > 50 pg/ml
Number of subjects: 802

Group type: EXPERIMENTAL
Intervention: BNP concentration median 11.3 pg/ml
Number of subjects: 802
Study: 17663620

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy for 2 months
Number of subjects: 26

Group type: COMPARATOR
Intervention: Information session (control)
Number of subjects: 26
Study: 16285355

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination antimicrobial therapy
Number of subjects: 0
Study: 12140300

Group type: EXPERIMENTAL
Intervention: Kidneys from donors without a heartbeat
Number of subjects: 244

Group type: COMPARATOR
Intervention: Kidneys from donors with a heartbeat
Number of subjects: 244
Study: 10189538

Group type: EXPERIMENTAL
Intervention: 5.07/10-g monofilament at five sites on the right foot
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Combination of sites 3 and 4 for monofilament testing
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Different methodologies for testing
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Monofilament with buckling force of 5 g and 15 g
Number of subjects: 332
Study: 7754764

Group type: EXPERIMENTAL
Intervention: alkylated immunoglobulin G intravenous preparation (IGIV) 200 mg/kg daily x 3 days + aspirin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: alkylated immunoglobulin G intravenous preparation (IGIV) 400 mg/kg daily x 3 days + aspirin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: native IGIV 200 mg/kg daily x 5 days + aspirin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: native IGIV 400 mg/kg daily x 5 days + aspirin
Number of subjects: 6
Study: 2148508

Group type: EXPERIMENTAL
Intervention: Longevity-Antihypertensive-Mixture (LAM)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Apocyhum Venetum L. Fluid (AVLF)
Number of subjects: 65
Study: 6945046

Group type: EXPERIMENTAL
Intervention: 5 mg PGE2 for primigravidas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg PGE2 for multigravidas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional induction by amniotomy and immediate oxytocin titration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional induction
Number of subjects: 0
Study: 30502372

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg monthly until complete resolution of SRF and IRF (intensive arm: SRF intolerant)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg with treatment aimed at resolution of all IRF only (relaxed arm: SRF tolerant)
Number of subjects: 349
Study: 28530238

Group type: EXPERIMENTAL
Intervention: Duloxetine (AD treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 25567329

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Yoga added to aerobic exercise
Number of subjects: 52
Study: 23684156

Group type: EXPERIMENTAL
Intervention: No-touch saphenous vein
Number of subjects: 108

Group type: COMPARATOR
Intervention: Radial artery graft
Number of subjects: 108

Group type: COMPARATOR
Intervention: Left internal thoracic artery graft
Number of subjects: 108
Study: 20568012

Group type: EXPERIMENTAL
Intervention: Peer-tutoring activities
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Good Behavior Game
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Peer-tutoring activities + Good Behavior Game
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 58
Study: 19910826

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 12
Study: 16951011

Group type: EXPERIMENTAL
Intervention: Content and Notification
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Notification Only
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Content Only
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Notification and Content
Number of subjects: 887

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 887
Study: 15587599

Group type: EXPERIMENTAL
Intervention: Ariston Liner and Ariston pHc (Vivadent, Schaan, FL)
Number of subjects: 0
Study: 11518443

Group type: EXPERIMENTAL
Intervention: Barthel Index (BI) assessment
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Lacunar infarcts
Number of subjects: 104

Group type: COMPARATOR
Intervention: Total anterior circulation infarcts
Number of subjects: 104
Study: 9466127

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d.
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: gemfibrozil 600 mg b.i.d. (in patients with > or = 20% reduction in triglyceride levels)
Number of subjects: 15
Study: 8536013

Group type: EXPERIMENTAL
Intervention: Lidocaine (5 ml intra-articular injection)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline with contrast dye (5 ml intra-articular injection)
Number of subjects: 60
Study: 3312048

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral indomethacin (IM)
Number of subjects: 60
Study: 29879676

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg)
Number of subjects: 996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 996
Study: 27113249

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 284
Study: 24428972

Group type: EXPERIMENTAL
Intervention: LTB4 added to activated CD8(+) T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment in SS asthma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment in SR asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultured CD8(+) T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cultured CD4(+) T cells from controls and patients with SS asthma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with SR asthma
Number of subjects: 0
Study: 22424016

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 190
Study: 19939870

Group type: EXPERIMENTAL
Intervention: Bupropion XR 150 mg
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 75 mg
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591